{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:44:38Z","timestamp":1790621078133,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.phrs.2021.105835","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T11:36:39Z","timestamp":1629718599000},"page":"105835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management"],"prefix":"10.1016","volume":"172","author":[{"given":"Gregory L.","family":"Hundemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.phrs.2021.105835_bib1","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1681\/ASN.2016121344","article-title":"How dangerous is hyperkalemia?","volume":"28","author":"Montford","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.phrs.2021.105835_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005428","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm creatinine measurements (SCREAM) project","volume":"6","author":"Bandak","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.phrs.2021.105835_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4A","key":"10.1016\/j.phrs.2021.105835_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(86)90334-7","article-title":"Potassium physiology","volume":"80","author":"Thier","year":"1986","journal-title":"Am. J. Med."},{"key":"10.1016\/j.phrs.2021.105835_bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fphys.2017.00371","article-title":"The structure and function of the Na,K-ATPase isoforms in health and disease","volume":"8","author":"Clausen","year":"2017","journal-title":"Front. Physiol."},{"issue":"7","key":"10.1016\/j.phrs.2021.105835_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/nu8070444","article-title":"Potassium intake, bioavailability, hypertension, and glucose control","volume":"8","author":"Stone","year":"2016","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr. Rev."},{"issue":"12","key":"10.1016\/j.phrs.2021.105835_bib10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/j.phrs.2021.105835_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/HCO.0000000000000709","article-title":"Hyperkalemia in heart failure","volume":"35","author":"Sidhu","year":"2020","journal-title":"Curr. Opin. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105835_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4239\/wjd.v7.i5.101","article-title":"Hyporeninemic hypoaldosteronism and diabetes mellitus: pathophysiology assumptions, clinical aspects and implications for management","volume":"7","author":"Sousa","year":"2016","journal-title":"World J. Diabetes"},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218739","article-title":"Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients \u2013 a population-based cohort study","volume":"14","author":"Adelborg","year":"2019","journal-title":"PLOS One"},{"key":"10.1016\/j.phrs.2021.105835_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","article-title":"Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system","volume":"245","author":"Nilsson","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"10","key":"10.1016\/j.phrs.2021.105835_bib15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1525-1497.1997.07128.x","article-title":"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis","volume":"12","author":"Perazella","year":"1997","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.phrs.2021.105835_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/20543581211017408","article-title":"Initial and recurrent hyperkalemia events in patients with CKD in older adults: a population-based cohort study","volume":"8","author":"Sriperumbuduri","year":"2021","journal-title":"Can. J. Kidney Health Dis."},{"key":"10.1016\/j.phrs.2021.105835_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/2054358120953287","article-title":"Derivation and internal validation of a clinical risk prediction tool for hyperkalemia-related emergency department encounters among hemodialysis patients","volume":"7","author":"Ronksley","year":"2020","journal-title":"Can. J. Kidney Health Dis."},{"issue":"5","key":"10.1016\/j.phrs.2021.105835_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1995.tb04482.x","article-title":"Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients","volume":"39","author":"Fogari","year":"1995","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"17","key":"10.1016\/j.phrs.2021.105835_bib19","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/archinternmed.2009.284","article-title":"Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy","volume":"169","author":"Weinberg","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.phrs.2021.105835_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfab076","article-title":"Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain","author":"Olry de Labry Lima","year":"2021","journal-title":"Clin. Kidney J."},{"issue":"5","key":"10.1016\/j.phrs.2021.105835_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Investigators","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"9386","key":"10.1016\/j.phrs.2021.105835_bib22","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.phrs.2021.105835_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2021.105835_bib25","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jchf.2019.07.010","article-title":"Hyperkalemia and treatment with RAAS inhibitors during acute heart failure hospitalizations and their association with mortality","volume":"7","author":"Beusekamp","year":"2019","journal-title":"JACC Heart Fail."},{"issue":"15","key":"10.1016\/j.phrs.2021.105835_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.phrs.2021.105835_bib27","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.phrs.2021.105835_bib28","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.phrs.2021.105835_bib29","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105835_bib30","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.phrs.2021.105835_bib31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105835_bib32","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jelectrocard.2018.06.018","article-title":"Electrocardiographic manifestations of severe hyperkalemia","volume":"51","author":"Littmann","year":"2018","journal-title":"J. Electrocardiol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105835_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004667","article-title":"Electrophysiology of hypokalemia and hyperkalemia","volume":"10","author":"Weiss","year":"2017","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib34","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ekir.2017.07.001","article-title":"Serum potassium levels and risk of sudden cardiac death among patients with chronic kidney disease and significant coronary artery disease","volume":"2","author":"Pun","year":"2017","journal-title":"Kidney Int. Rep."},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib35","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1186\/cc11872","article-title":"Severe hyperkalemia requiring hospitalization: predictors of mortality","volume":"16","author":"An","year":"2012","journal-title":"Crit. Care"},{"issue":"2","key":"10.1016\/j.phrs.2021.105835_bib36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.ajkd.2017.01.044","article-title":"Serum potassium, and associations with ESRD and mortality","volume":"70","author":"Chen","year":"2017","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.phrs.2021.105835_bib37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2215\/CJN.05850809","article-title":"Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study","volume":"5","author":"Korgaonkar","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105835_bib38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between serum potassium and outcomes in patients with reduced kidney function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.phrs.2021.105835_bib39","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008912","article-title":"Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes: a danish population-based cohort study","volume":"7","author":"Thomsen","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.phrs.2021.105835_bib40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ehjcvp\/pvv026","article-title":"Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction","volume":"1","author":"Krogager","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"3","key":"10.1016\/j.phrs.2021.105835_bib41","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.kint.2015.11.018","article-title":"Treatment of hyperkalemia: something old, something new","volume":"89","author":"Sterns","year":"2016","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.phrs.2021.105835_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/nu10030261","article-title":"Dietary approach to recurrent or chronic hyperkalaemia in patients with decreased kidney function","volume":"10","author":"Cupisti","year":"2018","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.phrs.2021.105835_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/nu11020338","article-title":"DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses","volume":"11","author":"Chiavaroli","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.phrs.2021.105835_bib44","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2215\/CJN.12990820","article-title":"Ambulatory treatments for RAAS inhibitor-related hyperkalemia and the 1-year risk of recurrence","volume":"16","author":"Hundemer","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105835_bib45","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern. Med."},{"issue":"22","key":"10.1016\/j.phrs.2021.105835_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"27","key":"10.1016\/j.phrs.2021.105835_bib47","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2021.105835_bib49","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2215\/CJN.09630818","article-title":"Clinical pharmacology in diuretic use","volume":"14","author":"Ellison","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105835_bib50","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2021.105835_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/2054358120965838","article-title":"Polysulfonate resins in hyperkalemia: a systematic review","volume":"7","author":"Wong","year":"2020","journal-title":"Can. J. Kidney Health Dis."},{"issue":"12","key":"10.1016\/j.phrs.2021.105835_bib52","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105835_bib53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/clc.20987","article-title":"Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy","volume":"35","author":"Chernin","year":"2012","journal-title":"Clin. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2021.105835_bib54","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","article-title":"Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age","volume":"179","author":"Noel","year":"2019","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.phrs.2021.105835_bib55","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjmed.2012.08.016","article-title":"Gastrointestinal adverse events with sodium polystyrene sulfonate (kayexalate) use: a systematic review","volume":"126","author":"Harel","year":"2013","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2021.105835_bib56","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4321\/S1130-01082013000400010","article-title":"Colonic necrosis due to calcium polystyrene sulfonate (kalimate) not suspended in sorbitol","volume":"105","author":"Castillo-Cejas","year":"2013","journal-title":"Rev. Esp. Enferm. Dig."},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib57","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3346\/jkms.2009.24.6.1207","article-title":"Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (kalimate) in a uremic patient","volume":"24","author":"Joo","year":"2009","journal-title":"J. Korean Med. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2021.105835_bib58","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical management of hyperkalemia","volume":"96","author":"Palmer","year":"2021","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"10.1016\/j.phrs.2021.105835_bib59","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/14656566.2016.1190333","article-title":"Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer","volume":"17","author":"Epstein","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.phrs.2021.105835_bib60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/acem.13868","article-title":"Patiromer for treatment of hyperkalemia in the emergency department: a pilot study","volume":"27","author":"Rafique","year":"2020","journal-title":"Acad. Emerg. Med."},{"issue":"10208","key":"10.1016\/j.phrs.2021.105835_bib61","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2021.105835_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.phrs.2021.105835_bib63","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.phrs.2021.105835_bib64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2021.105835_bib65","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2021.105835_bib66","article-title":"Patiromer acetate induced hypercalcemia: an unreported adverse effect","volume":"2019","author":"Bhattarai","year":"2019","journal-title":"Case Rep. Nephrol."},{"key":"10.1016\/j.phrs.2021.105835_bib67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5414\/CNCS109782","article-title":"Case report: patiromer-induced hypercalcemia","volume":"7","author":"Wiederkehr","year":"2019","journal-title":"Clin. Nephrol. Case Stud."},{"key":"10.1016\/j.phrs.2021.105835_bib68","unstructured":"VELTASSA [package insert], Relypsa, Inc., Redwood City, CA, 2018."},{"issue":"12","key":"10.1016\/j.phrs.2021.105835_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLOS One"},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib70","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/acem.13954","article-title":"Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase II, randomized, double-blind, placebo-controlled study (ENERGIZE)","volume":"27","author":"Peacock","year":"2020","journal-title":"Acad. Emerg. Med."},{"issue":"3","key":"10.1016\/j.phrs.2021.105835_bib71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.phrs.2021.105835_bib72","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib73","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000504078","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE","volume":"50","author":"Roger","year":"2019","journal-title":"Am. J. Nephrol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105835_bib74","first-page":"54","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-global study","volume":"7","author":"Zannad","year":"2020","journal-title":"ESC Heart Fail."},{"issue":"6","key":"10.1016\/j.phrs.2021.105835_bib75","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.phrs.2021.105835_bib76","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2019050450","article-title":"A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia","volume":"30","author":"Fishbane","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105835_bib77","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/phar.1906","article-title":"Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia","volume":"37","author":"Meaney","year":"2017","journal-title":"Pharmacotherapy"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:28:51Z","timestamp":1760912931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821004199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":77,"alternative-id":["S1043661821004199"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105835","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105835"}}